Five-year follow-up results from the phase III CLL14 trial demonstrated that over 60% of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus Gazyva (obinutuzumab) continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.
Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.
